Answers are grounded in this paper and cite their sources.
Randomized trial investigates steroid impact on mortality in HIV-negative individuals with PCP, suggesting clinical implications despite negative findings.
In this episode of Communicable, Navaneeth Narayanan and Josh Nosanchuk invite Virginie Lemiale and Elie Azoulay as well as fellow editor Emily McDonald—this time as guest—to discuss adjunctive steroid therapy for pneumocystis pneumonia (PCP) in HIV-negative individuals. In 2025, Lemiale and Azoulay published results from their double-blind, randomised controlled trial investigating steroid treatment for severe Pneumocystis jirovecii pneumonia (PIC trial) in the Lancet Respiratory Medicine [1]. At first glance, one might dismiss the study’s important clinical impact due the ‘negative' result of the primary outcome, mortality at 28 days, which just missed a statistically significant difference between groups.
No takes yet. Share an insight, caveat, or question.
Hostettler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: